Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 438

The DOI matches its Crossref record; 14 of the 14 references it cites were found in a registry or an index.

Phase II, Randomized Study of Concomitant Chemoradiotherapy Followed by Surgery and Adjuvant Capecitabine Plus Oxaliplatin (CAPOX) Compared With Induction CAPOX Followed by Concomitant Chemoradiotherapy and Surgery in Magnetic Resonance Imaging–Defined, Locally Advanced Rectal Cancer: Grupo Cáncer de Recto 3 Study

Open access
Fernández-Martos, Carlos, Pericay, Carles, Aparicio, Jorge, Salud, Antonieta, Safont, MariaJose, Massuti, Bertomeu, Vera, Ruth, Escudero, Pilar, Maurel, Joan, Marcuello, Eugenio, Mengual, Jose Luis, Saigi, Eugenio, Estevan, Rafael, Mira, Moises, Polo, Sonia, Hernandez, Ana, Gallen, Manuel, Arias, Fernando, Serra, Javier, Alonso, Vicente·2010·Journal of Clinical Oncology

Abstract

Purpose: The optimal therapeutic sequence of the adjuvant chemotherapy component of preoperative chemoradiotherapy (CRT) for patients with locally advanced rectal cancer is controversial. Induction chemotherapy before preoperative CRT may be associated with better efficacy and compliance. Patients and Methods: A total of 108 patients with locally advanced rectal cancer were randomly assigned to arm A—preoperative CRT with capecitabine, oxaliplatin, and concurrent radiation followed by surgery and four cycles of postoperative adjuvant capecitabine and oxaliplatin (CAPOX)—or arm B—induction CAPOX followed by CRT and surgery. The primary end point was pathologic complete response rate (pCR). Results: On an intention-to-treat basis, the pCR for arms A and B were 13.5% (95% CI, 5.6% to 25.8%) and 14.3% (95% CI, 6.4% to 26.2%), respectively. There were no statistically significant differences in other end points, including downstaging, tumor regression, and R0 resection. Overall, chemotherapy treatment exposure was higher in arm B than in arm A for both oxaliplatin (P < .0001) and capecitabine (P < .0001). During CRT, grades 3 to 4 adverse events were similar in both arms but were significantly higher in arm A during postoperative adjuvant CT than with induction CT in arm B. There were three deaths in each arm during the treatment period. Conclusion: Compared with postoperative adjuvant CAPOX, induction CAPOX before CRT had similar pCR and complete resection rates. It did achieve more favorable compliance and toxicity profiles. On the basis of these findings, a phase III study to definitively test the induction strategy is warranted.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1200/jco.2009.25.8541

Cites

14 of 14 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 14 references

Cited by

See all 438

Metadata

Authors
Fernández-Martos, C., Pericay, C., Aparicio, J., Salud, A., Safont, M., Massuti, B., Vera, R., Escudero, P., Maurel, J., Marcuello, E., Mengual, J. L., Saigi, E., Estevan, R., Mira, M., Polo, S., Hernandez, A., Gallen, M., Arias, F., Serra, J., & Alonso, V.
Venue
Journal of Clinical Oncology
Published
2010-02-10
Volume
28
Issue
5
Pages
859-865
ISSN
  • 0732-183X (ISSN-L)
  • 1527-7755
OpenAlex
W2047778994
Cited by
438
References
14
FWCI
11.68
Type
journal article
Language
en
Open access
bronze

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Phase II, Randomized Study of Concomitant Chemoradiotherapy Followed by Surgery and Adjuvant Capecitabine Plus Oxaliplatin (CAPOX) Compared With Induction CAPOX Followed by Concomitant Chemoradiotherapy and Surgery in Magnetic Resonance Imaging–Defined, Locally Advanced Rectal Cancer: Grupo Cáncer de Recto 3 Study. https://app.cochat.ai/papers/10.1200/jco.2009.25.8541
The paper
Fernández-Martos, C., Pericay, C., Aparicio, J., Salud, A., Safont, M., Massuti, B., Vera, R., Escudero, P., Maurel, J., Marcuello, E., Mengual, J. L., Saigi, E., Estevan, R., Mira, M., Polo, S., Hernandez, A., Gallen, M., Arias, F., Serra, J., & Alonso, V. (2010). Phase II, Randomized Study of Concomitant Chemoradiotherapy Followed by Surgery and Adjuvant Capecitabine Plus Oxaliplatin (CAPOX) Compared With Induction CAPOX Followed by Concomitant Chemoradiotherapy and Surgery in Magnetic Resonance Imaging–Defined, Locally Advanced Rectal Cancer: Grupo Cáncer de Recto 3 Study. Journal of Clinical Oncology. https://doi.org/10.1200/jco.2009.25.8541

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.